Background. Percutaneous endoscopic gastrostomy (PEG) tubes have largely replaced nasogastric tubes (NGTs) for nutritional support of patients with head and neck cancer undergoing curative (chemo) radiotherapy without any good scientific basis.Methods. A prospective study was conducted to compare PEG tubes and NGTs in terms of nutritional outcomes, complications, patient satisfaction, and cost.Results. There were 32 PEG and 73 NGT patients. PEG patients sustained significantly less weight loss at 6 weeks post-treatment (median 0.8 kg gain vs 3.7 kg loss, p < .001), but had a high insertion site infection rate (41%), longer median duration of use (146 vs 57 days, p < .001), and more grade 3 dysphagia in disease-free survivors at 6 months (25% vs 8%, p ¼ .07). Patient self-assessed general physical condition and overall quality of life scores were similar in both groups. Overall costs were significantly higher for PEG patients.Conclusion. PEG tube use should be selective, not routine, in this patient population.

Percutaneous endoscopic gastrostomy (PEG) tubes have largely replaced nasogastric tubes (NGT) for nutritional support of patients with head and neck cancer undergoing curative (chemo)radiotherapy without any good scientific basis. A randomized trial was conducted to compare PEG tubes and NGT in terms of nutritional outcomes, complications, patient satisfaction and cost. The study was closed early because of poor accrual, predominantly due to patients' reluctance to be randomized. There were 33 patients eligible for analysis. Nutritional support with both tubes was good. There were no significant differences in overall complication rates, chest infection rates or in patients' assessment of their overall quality of life. The cost of a PEG tube was 10 times that of an NGT. The duration of use of PEG tubes was significantly longer, a median 139 days compared with a median 66 days for NGT. We found no evidence to support the routine use of PEG tubes over NGT in this patient group.

No abstract

Introduction Regional cancer patients face various barriers in accessing specialist cancer services. Teletrials are a new model of care that utilise telemedicine technology to enable access to and participation in clinical trials close to home. The present study aimed to explore the experiences of regional cancer patients and their carers while participating in a teletrial, and those of regional patients who travelled to a metropolitan centre for trial participation. Methods A concurrent, mixed methods study design was used to address the study aim. Patient quality of life data were gathered for both groups and an audio-recorded semi-structured interview undertaken to explore patients’ and carers’ experiences of the two modes of trial participation. Greater weighting was given to the qualitative data. Results Participants described teletrials as an acceptable and valuable initiative that reduced overall burden of trial participation. Irrespective of mode of delivery, patients and carers identified access to trials and specialist cancer services as an important equity issue for regional cancer patients. Discussion From the perspective of regional cancer patients and carers, a teletrial offers convenient, acceptable access to a clinical trial. Although not all patients may want to engage in a teletrial, patients and carers agree that it offers equity of opportunity for trial participation, irrespective of where people live.

ConclusionWhen given the opportunity, rural cancer patients are willing to participate in cancer clinical trials. Clinical trial networks and teletrials can overcome the structural and clinical barriers that prevent participation. However, evaluation of their costs and standardised measures of participation are required. Attention also needs to be focussed at the physician level, as the physician can initiate discussion with patients regarding participation and address misconceptions about clinical trials.

Aims: To obtain an estimate of dietary fibre and fluid intake in Australian men undergoing prostate radiotherapy and to establish feasibility and patient compliance with recording normal diet without intervention during the radical course of radiotherapy.Methods: Eleven participants were enrolled and treated with 74–78 Gray (Gy) to the prostate over 8 weeks. Participants were instructed to record a diary of their food and fluid intake and bowel motions for the duration of treatment. Treating radiation therapists were instructed to initial the diet diary daily. Diet diaries were assessed for compliance by analysing the number of days over the treatment period and the number of diary pages submitted. The diet diaries were analysed for nutrient intake of fibre and fluids.Results: A total of 10 of 11 participants submitted a diet record for the full duration of treatment with a median compliance of 100% (range 90.4–100%) of days recorded. The mean (standard deviation) of fibre and fluids recorded in the diets were 21.5 g (5.5) and 2227.1 g (733.1), respectively.Conclusions: It is feasible for patients to record a diet diary over a radical course of prostate radiotherapy. In this study, most patients were highly compliant with submitting a diet record for each day during treatment.

No abstract

No abstract